Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, David S. Shames, Marcin Kowanetz et al.|Nature Medicine|2018Cited by 1.2k
High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and NeckDavid S. Shames, Lukas C. Amler|PLoS ONE|2013Cited by 70